-
BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment
•
The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) for its first-in-class selective tyrosine kinase 2 (TYK2) inhibitor, Sotyktu (deucravacitinib). The drug is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Mechanism of…
-
CDE Grants Priority Review to Pearl Biotech’s Breatinib for Glioblastoma Treatment
•
China’s Center for Drug Evaluation (CDE) has indicated that Beijing Pearl Biotechnology Co., Ltd’s breatinib has obtained priority review status for the treatment of WHO grade 4 astrocytoma with isocitrate dehydrogenase (IDH) mutation and PTPRZ1-MET (ZM) fusion gene, or adult glioblastoma (GBM) patients who have relapsed after, or become intolerant…
-
Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced demand for COVID-19 products impacted global growth, resulting in a 1% year-on-year (YOY) increase at constant exchange rates over the first nine months, with total sales amounting to CHF 44.1 billion (USD 49.4 billion). Excluding…
-
BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study of its anti-PD-1 drug Opdivo (nivolumab) formulated as a subcutaneous injection. The study, conducted in pre-treated advanced or metastatic clear cell renal cell carcinoma (ccRCC) patients, utilized Halozyme Therapeutics’ (NASDAQ: HALO) proprietary hyaluronidase (rHuPH20) for…
-
Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases
•
Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE HealthCare (NASDAQ: GEHC) to develop peripheral focused ultrasound (PFUS) technology. This non-invasive approach aims to regulate metabolic function in the treatment of chronic diseases such as type 2 diabetes (T2D) and obesity. PFUS Technology and…
-
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based Daiichi Sankyo (TYO: 4568) focused on the development and commercialization of three potential first-in-class deruxtecan-based antibody-drug conjugate (ADC) candidates. This partnership aims to advance innovative treatments for various types of cancer. ADC Candidates and Development…
-
HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy
•
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD) from the US FDA for its RNA editing therapy, HG204, targeting MECP2 duplication syndrome (MDS). This designation is a significant step forward in the development of novel treatments for this rare pediatric neurodevelopmental…
-
Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion
•
Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of its expanded manufacturing plant in Shanghai, China. The expansion, which was completed in 15 months, is set to significantly enhance the company’s manufacturing capabilities by doubling its current capacity. Shanghai Plant’s Strategic ImportanceThe firm’s China…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
